Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib versus placebo before topotecan in extensive-stage small cell lung cancer
2022-502357-34-00Phase 3Authorised
- Sponsor
- Pharmacosmos
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Trilaciclib + topotecan with Placebo + topotecan (2 arms). Primary endpoint: Overall survival. Planned start Sep 2023; status: authorised.
02
Drugs
trilaciclibtopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-502357-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502357-34-00.